High Alpha Temporal Top-Z Rate Reorganization Mediates Dose–Motor Coupling Following NeuroEPO Treatment

Read full text Summarise with VIRAT
Authors: Mengsha Qi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This OSF project provides supporting materials for the manuscript "High-Alpha Temporal Topography Reorganization Mediates NeuroEPO Effects on Motor Function in Parkinson’s Disease". Files included: NeuroEPO_PD_EEG_NeuroGroup_Wide_v1.csv: Quantitative EEG dataset for the NeuroEPO treatment group. This file contains frequency-specific spectral power features in wide format, derived from post-intervention EEG recordings across 19 scalp channels. NeuroEPO_PD_EEG_PlaceboGroup_Wide_v1.csv: Quantitative EEG dataset for the placebo group. This file contains frequency-specific spectral power features in wide format, derived from post-intervention EEG recordings across 19 scalp channels. NeuroEPO_PD_MotorAndCognition_Clinical_LongFormat_v4_WIDE_IDNAMING_FIXED.csv: Final longitudinal clinical, motor, and cognitive dataset used in the manuscript analyses. The file is organized in long format and contains 55 participants represented across pre- and post-intervention observations. Variables include group assignment, participant identifiers, cumulative dose, clinical assessment date, MDS-UPDRS-III item-level motor measures, disease severity and progression ratings, age, education, and cognitive/neuropsychological outcomes. NeuroEPO_PD_MotorAndCognition_Dictionary_v3_MATCHED_TO_v4.xlsx: Variable dictionary corresponding exactly to the final longitudinal clinical dataset. It includes variable abbreviations, source tests, full English names, coding rules or scoring directions where applicable, and category labels, with variable order matched to the V4 clinical data file. NeuroEPO 方案 fase II III.pdf: Clinical trial protocol for the Phase II/III randomized, double-blind, placebo-controlled NeuroEPO study in patients with Parkinson’s disease. The protocol describes study design, intervention schedule, eligibility criteria, and primary and secondary outcomes. All shared data are fully de-identified and use anonymous participant IDs to protect privacy. These materials are shared under the CC-BY 4.0 license to support transparency, reproducibility, and secondary analysis of the clinical, motor, cognitive, and quantitative EEG findings related to NeuroEPO treatment in Parkinson’s disease.

Fields of Study & Subjects

Parkinson's Disease Mechanisms and Treatments Deep Brain Stimulation and Movement Disorders Transcranial Magnetic Stimulation Studies

Publication details

Publication date
1 January 2026
Language
EN
Document type
Preprint